1. **Executive Session** 6:30 - 7:00
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

2. **Introductions and Approval of DUR Board Minutes** 7:00 - 7:05
   (Public Comment Prior to Board Action)

3. **DVHA Pharmacy Administration Updates** 7:05 - 7:15
   - Medications to be Dispensed as Initial 15 Day Supply

4. **Medical Director Update** 7:15 - 7:20
   - Clinical Programs Update
   - Prescriber Comments

5. **Follow-up Items from Previous Meetings** 7:20 - 7:25
   - Citalopram > 40 mg/day (new FDA update)

6. **RetroDUR/DUR** 7:25 - 7:55
   - Narcotic Analgesics – Short Acting
   - Psychotropic Medication Use in Children SFY 2009 – 2011
   - Psychotropic Medication Use in Children in Foster Care SFY 2009 - 2011

7. **Clinical Update: Drug Reviews** 7:55 – 8:30
   (Public comment prior to Board action)
   - **Abbreviated Drug Reviews**
     - Conzip® (tramadol extended release) Capsule
     - Gralise® (gabapentin) Tablet
     - Juvisync® (sitagliptin/simvastatin) Tablet
     - Orencia® (abatacept) Subcutaneous Injection
   - **Full New Drug Reviews**
     - Onfi® (clobazam) Tablet
     - Firazyr® (icatibant) Prefilled Syringe for Subcutaneous Injection
     - Solesta® Gel Prefilled Syringe for Submucosal Injection
8. Therapeutic Drug Classes – Periodic Review  

Class review documents available on DVHA web site 4/10/2012 @ 12 Noon
- Anti-Fungals – Oral
- Anti-Diabetics – Oral - Thiazolidinediones
- Insulins
- Osteoporosis Treatments

9. New Managed Therapeutic Drug Classes  

Antihypertensives: Alpha Blockers

10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products

None

11. General Announcements

Selected FDA Safety Alerts
- Proton Pump Inhibitors – Drug Safety Communication – Clostridium difficile associated diarrhea
- Statins and Protease Inhibitors – Risk of Muscle Injury
- Statins – Labelling Changes
- Tysabri® - Drug Safety Communication – Update of Risk Factors for PML
- Victrelis® - Drug Safety Communication – Important Drug Interaction with Certain HIV Protease Inhibitors

12. Adjourn